Switch theme
Sign up to access all valuation multiples
PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Diseases. The company derives its revenue from the sales of medicine products. Geographically, the company generates maximum revenue from America, followed by Europe, Asia (excluding Taiwan), and Taiwan.
2000
350
LTM Revenue $437M
LTM EBITDA $136M
$5.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PharmaEssentia has a last 12-month revenue (LTM) of $437M and a last 12-month EBITDA of $136M.
In the most recent fiscal year, PharmaEssentia achieved revenue of $334M and an EBITDA of $116M.
PharmaEssentia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmaEssentia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $437M | XXX | $334M | XXX | XXX | XXX |
| Gross Profit | $388M | XXX | $294M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $136M | XXX | $116M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 35% | XXX | XXX | XXX |
| EBIT | $119M | XXX | $59.6M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $142M | XXX | $102M | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, PharmaEssentia's stock price is TWD 548 (or $19).
PharmaEssentia has current market cap of TWD 182B (or $6.3B), and EV of TWD 161B (or $5.5B).
See PharmaEssentia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.5B | $6.3B | XXX | XXX | XXX | XXX | $0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, PharmaEssentia has market cap of $6.3B and EV of $5.5B.
PharmaEssentia's trades at 16.6x EV/Revenue multiple, and 47.6x EV/EBITDA.
Equity research analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaEssentia has a P/E ratio of 44.0x.
See valuation multiples for PharmaEssentia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.3B | XXX | $6.3B | XXX | XXX | XXX |
| EV (current) | $5.5B | XXX | $5.5B | XXX | XXX | XXX |
| EV/Revenue | 12.7x | XXX | 16.6x | XXX | XXX | XXX |
| EV/EBITDA | 40.9x | XXX | 47.6x | XXX | XXX | XXX |
| EV/EBIT | 46.5x | XXX | 92.9x | XXX | XXX | XXX |
| EV/Gross Profit | 14.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 44.0x | XXX | 61.5x | XXX | XXX | XXX |
| EV/FCF | 24.7x | XXX | 98.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmaEssentia's last 12 month revenue growth is 58%
PharmaEssentia's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.7M for the same period.
PharmaEssentia's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaEssentia's rule of X is 176% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PharmaEssentia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 58% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 83% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 45% | XXX | 93% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 176% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 70% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaEssentia acquired XXX companies to date.
Last acquisition by PharmaEssentia was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmaEssentia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PharmaEssentia founded? | PharmaEssentia was founded in 2000. |
| Where is PharmaEssentia headquartered? | PharmaEssentia is headquartered in Taiwan. |
| How many employees does PharmaEssentia have? | As of today, PharmaEssentia has 350 employees. |
| Who is the CEO of PharmaEssentia? | PharmaEssentia's CEO is Mr. Ko-Chung Lin. |
| Is PharmaEssentia publicy listed? | Yes, PharmaEssentia is a public company listed on TAI. |
| What is the stock symbol of PharmaEssentia? | PharmaEssentia trades under 6446 ticker. |
| When did PharmaEssentia go public? | PharmaEssentia went public in 2014. |
| Who are competitors of PharmaEssentia? | Similar companies to PharmaEssentia include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of PharmaEssentia? | PharmaEssentia's current market cap is $6.3B |
| What is the current revenue of PharmaEssentia? | PharmaEssentia's last 12 months revenue is $437M. |
| What is the current revenue growth of PharmaEssentia? | PharmaEssentia revenue growth (NTM/LTM) is 58%. |
| What is the current EV/Revenue multiple of PharmaEssentia? | Current revenue multiple of PharmaEssentia is 12.7x. |
| Is PharmaEssentia profitable? | Yes, PharmaEssentia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PharmaEssentia? | PharmaEssentia's last 12 months EBITDA is $136M. |
| What is PharmaEssentia's EBITDA margin? | PharmaEssentia's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of PharmaEssentia? | Current EBITDA multiple of PharmaEssentia is 40.9x. |
| What is the current FCF of PharmaEssentia? | PharmaEssentia's last 12 months FCF is $224M. |
| What is PharmaEssentia's FCF margin? | PharmaEssentia's last 12 months FCF margin is 51%. |
| What is the current EV/FCF multiple of PharmaEssentia? | Current FCF multiple of PharmaEssentia is 24.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
